EP0285884A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Process to produce 2', 3'-Dideoxynucleosides
Assignee: Bristol Myers Squibb Co
•
Filing: 1988-03-18
•
Granted: —
•
Expires: 2008-03-18
Abstract
Abstract There is disclosed a novel process to produce 2',3'-dideoxynucleosides such as, for example, 2',3'-dideoxycytidine, in high yields. More particularly, the various stereoisomers of 2',3'-dideoxynucleosides are obtained. The alpha - and beta -(L)-2',3'-dideoxynucleosides and certain alpha -(D)-2',3'-dideoxynucleosides are obtained as stereochemically pure compounds not heretofore obtained. The compounds so produced are useful as antiviral and antibiotic agents.
Inventors
- 👤 Vittorio Farina
- 👤 John C. Martin
- 👤 Daniel A- Benigni
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-29 23:00
CPC Classifications
C; C07; C07D; C07D473/00; C07D405/00; C07D405/02; C07D405/04
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
397 words
A process for producing a 2ʹ,3ʹ-dideoxynucleoside represented by the formula wherein B is a base selected from the group of purine and pyrimidine bases and R is a member selected from H and hydroxy-protecting groups, which comprises the steps of: (a) converting a member of the group consisting of L-and D-γ-carboxy-γ-butyrolactone of the formula to a 5-O-hydroxy-protecting group-methyl-γ-butyrolactone of the formula wherein R is a hydroxy-protecting group, by reacting the compound of Formula 1 with a carboxy group reducing agent followed by reacting the resulting hydroxymethyl group with a hydroxy-protecting group reagent; (b) converting the intermediate from step (a), Formula 2, to the 5-O-hydroxy-protecting group-methyl-2,3-dideoxy-D-or -L-pentofuranose of the formula wherein R is a hydroxy-protecting group, by reacting the compound of Formula 2 with a carbonyl group reducing agent; (c) converting the intermediate from step (b), Formula 3, to a 1-O-activating-group-5-O-hydroxy-protecting group-2,3-dideoxy-D- or -L-pentofuranose of the formula wherein R is a hydroxy-protecting group and A is an O-activating group selected from alkylcarbonyl, arylcarbonyl, alkylthiocarbonyl, arylthiocarbonyl, alkylsulfonyl, arylsulfonyl and carbonate groups, wherein the alkyl moiety may be an unsubstituted or substituted C₁-C₃ alkyl group and the aryl moiety may be an unsubstituted or substituted phenyl group and wherein the substituent on the alkyl and aryl moieties may be selected from 1 to 3 groups selected from halo and C₁-C₃ alkoxy groups, by reacting the compound of Formula 4 with an acylating or sulfonating or carbonylating agent corresponding to the group A above; (d) converting the intermediate from step (c), Formula 4, by reaction with a compound having one of the formulas HX and TMSX to the 1-leaving-group-5-O-protecting group-2,3-dideoxy-D- or -L-pentofuranose of the formula wherein R is a hydroxy-protecting group and X is a leaving group selected from F, Cl, Br and I by reacting the compound of Formula 4 with a compound having one of the formulas HX and TMSX; (e) reacting the intermediate from step (d), Formula 5 with an activated base selected from purine and pyrimidine bases, wherein the base has been activated by means of reacting the pendant amino and hydroxy groups on the nucleus of the given base with an activating compound selected from silylating and acetylating and benzoylating agents, in the presence of one of a Bronsted acid and a Lewis acid and in the presence of a solvent selected from polar and non-polar solvents; and (f) recovering the dideoxynucleoside from step (e) above.
Claim 2
Dependent Claim
397 words
A process for producing a 2ʹ,3ʹ-dideoxynucleoside represented by the formula wherein B is a base selected from the group of purine and pyrimidine bases and R is a member selected from H and hydroxy-protecting groups, which comprises the steps of: (a) converting a member of the group consisting of L-and D-γ-carboxy-γ-butyrolactone of the formula to a 5-O-hydroxy-protecting group-methyl-γ-butyrolactone of the formula wherein R is a hydroxy-protecting group, by reacting the compound of Formula 1 with a carboxy group reducing agent followed by reacting the resulting hydroxymethyl group with a hydroxy-protecting group reagent; (b) converting the intermediate from step (a), Formula 2, to the 5-O-hydroxy-protecting group-methyl-2,3-dideoxy-D-or -L-pentofuranose of the formula wherein R is a hydroxy-protecting group, by reacting the compound of Formula 2 with a carbonyl group reducing agent; (c) converting the intermediate from step (b), Formula 3, to a 1-O-activating-group-5-O-hydroxy-protecting group-2,3-dideoxy-D- or -L-pentofuranose of the formula wherein R is a hydroxy-protecting group and A is an O-activating group selected from alkylcarbonyl, arylcarbonyl, alkylthiocarbonyl, arylthiocarbonyl, alkylsulfonyl, arylsulfonyl and carbonate groups, wherein the alkyl moiety may be an unsubstituted or substituted C₁-C₃ alkyl group and the aryl moiety may be an unsubstituted or substituted phenyl group and wherein the substituent on the alkyl and aryl moieties may be selected from 1 to 3 groups selected from halo and C₁-C₃ alkoxy groups, by reacting the compound of Formula 4 with an acylating or sulfonating or carbonylating agent corresponding to the group A above; (d) converting the intermediate from step (c), Formula 4, by reaction with a compound having one of the formulas HX and TMSX to the 1-leaving-group-5-O-protecting group-2,3-dideoxy-D- or -L-pentofuranose of the formula wherein R is a hydroxy-protecting group and X is a leaving group selected from F, Cl, Br and I by reacting the compound of Formula 4 with a compound having one of the formulas HX and TMSX; (e) reacting the intermediate from step (d), Formula 5 with an activated base selected from purine and pyrimidine bases, wherein the base has been activated by means of reacting the pendant amino and hydroxy groups on the nucleus of the given base with an activating compound selected from silylating and acetylating and benzoylating agents, in the presence of one of a Bronsted acid and a Lewis acid and in the presence of a solvent selected from polar and non-polar solvents; and (f) recovering the dideoxynucleoside from step (e) above.
Claim 3
Dependent Claim
41 words
A process according to claim 1 wherein the reducing agent used in steps (a) and (b) is selected from BH₃(B₂H₆), BH₃.SMe₂ NaBH₄, NaBH₄ plus one of LiCl and AlCl₃ and BF₃, LiAlH₄, LiAlH(OMe)₃, and LiAlH(O- t -BU)₃, and dialkylboranes including (Sia)₂BH..
Claim 4
Dependent Claim
18 words
A process according to claim 1 wherein the reducing agent used in step (a) is BH₃ or BH₃.SMe₂.
Claim 5
Dependent Claim
41 words
A process according to anyone of the preceding claims wherein the hydroxy-protecting group used in step (a) is selected from unsubstituted and substituted benzyl, trialkylsilyl, alkylarylsilyl, unsubstituted and substituted alkyl, vinyl, benzoyl, mesitoyl, pivaloyl, unsubstituted and substituted acetoxy, and carbonate groups.
Claim 6
Dependent Claim
12 words
A process according to claim 4 wherein the hydroxy-protecting group is benzyl.
Claim 7
Dependent Claim
23 words
A process according to anyone of the preceding claims wherein the O-activating group used in step (c) is selected from alkylcarbonyl and arylcarbonyl.
Claim 8
Dependent Claim
20 words
A process according to claim 6 wherein the O-activating group used in step (c) is selected from acetyl and benzoyl.
Claim 9
Dependent Claim
82 words
A process according to anyone of the preceding claims wherein in step (e) the base, B, component is selected from purine and pyrimidine bases wherein (1) the bases are activated by reaction with a halotrialkylsilane as the silylating agent wherein the halo is selected from bromo and iodo and (2) the bases are selected from halopurine bases which are sufficiently reactive with the1-leaving-group-5-O-protecting group-2ʹ,3ʹ-dideoxypentofuranose having Formula 5 so as not to require activation of the base by reaction with an activating compound.
Claim 10
Dependent Claim
46 words
A process according to claim 8 wherein the base component, B, is selected from purine and pyrimidine bases that are activated by reaction with a halotrimethylsilane and wherein the reaction in step (e) is carried out in a non-polar selected from CHCl₃, CHCl₂, ClCH₂-CH₂Cl, and CCl₄
Claim 11
Dependent Claim
43 words
A process according to claim 9 wherein the base, B, component is selected from the group of purine bases consisting of 6-aminopurin-9-yl, 2-aminopurin-9-yl, 2,6-diaminopurin-9-yl, 2-amino-6-hydroxypurin-9-yl and 6-hydroxypurin-9-yl and the group of pyrimidine bases consisting of 2,6-dihydroxypyrimidin-3-yl, 5-methyl-2,6-dihydroxypryimidin-3-yl, 2-hydroxy-6-aminopyrimidin-3-yl, 5-vinyl-2,6-dihydroxypyrimdin-3-yl, 5-halovinyl-2,6-dihydroxypyrimidin-3-yl, 5-halomethyl-2,6-dihydroxypyrimidin-3-yl, and 5-haloethyl-2,6-dihydroxypryrimidin-3-yl.
Claim 12
Dependent Claim
25 words
A process according to anyone of the preceding claims including the additional step, following step (e) and before step (f), of removing the 5-O-hydroxy-protecting group.
Claim 13
Dependent Claim
44 words
A process according to claim 11 wherein the 5-O-hydroxy protecting group is selected from benzyl and benzoyl groups and said group is removed by means selected from catalytic hydrogenation of the benzyl group using H₂/PdCl₂ reagent and NH₃ hydrolysis of the benzoyl group, respectively.
Claim 14
Dependent Claim
28 words
A compound having the formula wherein R is a hydroxy-protecting group and A is an O-activating group selected from alkylcarbonyl, arylcarbonyl, alkylthiocarbonyl, arylthiocarbonyl, alkylsulfonyl, arylsulfonyl and carbonate groups.
Claim 15
Dependent Claim
28 words
A compound having the formula wherein R is a hydroxy-protecting group and A is an O-activating group selected from alkylcarbonyl, arylcarbonyl, alkylthiocarbonyl, arylthiocarbonyl, alkylsulfonyl, arylsulfonyl and carbonate groups.
Claim 16
Dependent Claim
17 words
A compound according to claim 13 wherein R is PhCH₂ (benzyl) and wherein A is CH₃CO (acetyl).
Claim 17
Dependent Claim
21 words
A compound having the formula wherein R is a hydroxy-protecting group and X is selected from F, Cl, Br and I.
Claim 18
Dependent Claim
21 words
A compound having the formula wherein R is a hydroxy-protecting group and X is selected from F, Cl, Br and I.
Claim 19
Dependent Claim
16 words
A compound according to claim 15 wherein R is selected from PhCH₂ (benzyl) and benzoyl groups.
Claim 20
Dependent Claim
11 words
The compounds having the formulae: and the pharmaceutically acceptable salts thereof.
Claim 21
Dependent Claim
11 words
The compounds having the formulae: and the pharmaceutically acceptable salts thereof.
Claim 22
Dependent Claim
25 words
An (L)-2ʹ,3ʹ-dideoxynucleoside having the formula B is a member selected from the group consisting of purine and pyrimidine bases, and the pharmaceutically acceptable salts thereof.
Claim 23
Dependent Claim
25 words
An (L)-2ʹ,3ʹ-dideoxynucleoside having the formula B is a member selected from the group consisting of purine and pyrimidine bases, and the pharmaceutically acceptable salts thereof.
Claim 24
Dependent Claim
9 words
The compounds according to claim 18 having the formulae
Claim 25
Dependent Claim
24 words
A pharmaceutical composition comprising at least one 2ʹ,3ʹ-dideoxynucleoside as defined in claims 17 to 19, optionally together with a pharmaceutically acceptable carrier and/or diluent.
Claim 26
Dependent Claim
40 words
A process for preparing the pharmaceutical composition of claim 20 which comprises providing a compound as defined in claims 17 to 19 in the form of a pharmaceutical composition and optionally incorporating it into a pharmaceutically acceptable carrier and/or diluent.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.